Jade Biosciences (JBIO) Cash from Operations (2020 - 2026)

Jade Biosciences has reported Cash from Operations for 7 years, with the latest figure at 24100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 28.49% year-over-year to 24100000.0; the trailing twelve-month figure through Mar 2026 stood at 100032000.0 (down 107.65% YoY), and the FY2025 full-year result was 94689000.0, down 33.0% from the prior year.
• Cash from Operations for Q1 2026 stood at 24100000.0, up from 33689000.0 in the prior quarter.
• The five-year high for Cash from Operations was 5661000.0 in Q1 2022, with the low at 33689000.0 in Q4 2025.
• Historically, Cash from Operations has averaged 16736125.0 across 5 years, with a median of 15277000.0 in 2023.
• Annual changes were most pronounced in 2024 — Cash from Operations surged 56.43% — and 2025, when it tumbled 224.9%.
• Jade Biosciences' Cash from Operations stood at 14865000.0 in 2022, then gained by 0.44% to 14800000.0 in 2023, then plunged by 52.8% to 22614000.0 in 2024, then plunged by 48.97% to 33689000.0 in 2025, then rose by 28.46% to 24100000.0 in 2026.
• The last three Cash from Operations figures came in at 24100000.0 (Q1 2026), 33689000.0 (Q4 2025), and 22100000.0 (Q3 2025), per Business Quant data.